Bristol-Myers Squibb Co (LIM:BMY) Change In Receivables : $-387 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Bristol-Myers Squibb Co Change In Receivables?

Bristol-Myers Squibb Co's change in receivables for the quarter that ended in Sep. 2024 was $661 Mil. It means Bristol-Myers Squibb Co's Accounts Receivable declined by $661 Mil from Jun. 2024 to Sep. 2024 .

Bristol-Myers Squibb Co's change in receivables for the fiscal year that ended in Dec. 2023 was $-995 Mil. It means Bristol-Myers Squibb Co's Accounts Receivable increased by $995 Mil from Dec. 2022 to Dec. 2023 .

Bristol-Myers Squibb Co's Accounts Receivable for the quarter that ended in Sep. 2024 was $9,317 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Bristol-Myers Squibb Co's Days Sales Outstanding for the three months ended in Sep. 2024 was 71.49.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Bristol-Myers Squibb Co's liquidation value for the three months ended in Sep. 2024 was $-59,722 Mil.

Bristol-Myers Squibb Co Change In Receivables Historical Data

The historical data trend for Bristol-Myers Squibb Co's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Change In Receivables Chart

Bristol-Myers Squibb Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

752.00

-646.00

-1,054.00

-663.00

-995.00

Bristol-Myers Squibb Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Receivables	Get a 7-Day Free Trial															-247.00	-508.00	479.00	-1,019.00	661.00

Bristol-Myers Squibb Co Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-387 Mil.

Bristol-Myers Squibb Co (LIM:BMY) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Bristol-Myers Squibb Co's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	9317	/	11892	*	91
=	71.49

2. In Ben Graham's calculation of liquidation value, Bristol-Myers Squibb Co's accounts receivable are only considered to be worth 75% of book value:

Bristol-Myers Squibb Co's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8094	-	76470	+	0.75 * 9317	+	0.5 * 3332
=	-59,722

Bristol-Myers Squibb Co Change In Receivables Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Bristol-Myers Squibb Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (LIM:BMY) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

BMYMP.PFD:USA BMY:USA BMY:Mexico 1BMY:Italy BRMd:UK 0R1F:UK BRM:Germany BRM:Germany BRM:Germany BRM:Germany BMYB34:Brazil BMYS:Austria BMY:Argentina

Address

Route 206 and Province Line Road, Princeton, New Jersey, NJ, USA, 08543

Website

https://www.bms.com

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.